Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 155 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Plasma sample collection Clear all

Conditions: Healthy Volunteers, Syphilis Serologic Assay Development, Blood Specimen Collection, Diagnostic Assay Development, Serum Specimen Collection
Interventions: ALPCO Syphilis-T, ALPCO Syphilis-NT CLIA Kits; Device
Lead sponsor: American Laboratory Products Company; Industry
Eligibility: 22 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Salem, New Hampshire

Conditions: Hiv
Interventions: Anoscopy with Rectal Tissue Sampling, Phlebotomy, Female Genital Tract Sampling; Procedure
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Pancreatic Cancer
Interventions: Blood draw; Procedure
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Sinusitis
Interventions: Zithromax (azithromycin) 500mg tablets, Endoscopic Sinus Surgery, Blood sampling for hematology, Blood sampling for plasma chemistry profile, Serum pregnancy test (for women of child-bearing potential); Drug · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 18
States / cities: Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 11 more

Conditions: Rheumatoid Arthritis, Interstitial Lung Disease
Interventions: Research Testing Performed (Laboratory), Information Collected as Standard of Care, Research Testing Performed; Genetic · Diagnostic Test · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 90 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 4
States / cities: San Francisco, California • Aurora, Colorado • Kansas City, Kansas + 1 more

Conditions: Prostate Cancer
Interventions: Collection of plasma samples; Other
Lead sponsor: DiaCarta, Inc.; Industry
Eligibility: 30 Years to 85 Years · Male only
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Gainesville, Florida • Jacksonville, Florida • New York, New York + 2 more

Conditions: Glioblastoma
Interventions: Cognitive Assessment, Blood Collection, Bioenergetic Profiling; Procedure · Diagnostic Test
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Breast Cancer, Ductal Carcinoma In Situ
Interventions: Survey Assessments, Diet Recall, Blood Biomarker Collection; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: polymorphism analysis, high performance liquid chromatography, laboratory biomarker analysis, radiomammography; Genetic · Other · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 180
States / cities: Augusta, Georgia • Aurora, Illinois • Bloomington, Illinois + 111 more

Conditions: Prostate Cancer
Interventions: docetaxel, Blood draws; Drug · Other
Lead sponsor: Saladax Biomedical, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 20
States / cities: Beaver, Pennsylvania • Bethel Park, Pennsylvania • Farrell, Pennsylvania + 13 more

Conditions: Rehumanization Intervention, Control Intervention
Interventions: Rehumanized Intervention, Control Intervention, Clinical Interview, Self-Report Measures, Blood Draw; Other · Diagnostic Test
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Prostate Cancer
Interventions: PROSTVAC-V/F, Nivolumab, Prostatectomy, Biopsy, Tylenol; Biological · Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: Lumbar puncture, Blood draw, Magnetic Resonance Imaging (MRI); Procedure
Lead sponsor: Emory University; Other
Eligibility: 60 Years to 85 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Lymphoma, Refractory B-Cell Lymphoma, Lymphoma, B-Cell, DLBCL NOS, High-grade B-cell Lymphoma, Multiple Myeloma
Interventions: Activities of Daily Living/ADLs, Instrumental Activity of Daily Living, Timed Up and Go, Cognition, Geriatric Depression Scale, Social Support, Brief Test of Attention, Trail Making Test, Controlled Oral Word Association Test, Hopkins Verbal Learning Test-Revised, Blood draw; Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Septic Shock
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cancer
Interventions: Biospecimen collection; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Opioid-use Disorder
Interventions: Blood sample collection, Urine sample collection; Diagnostic Test
Lead sponsor: Indivior Inc.; Industry
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 11
States / cities: Hamilton, Alabama • Tampa, Florida • Prairie Village, Kansas + 7 more

Conditions: IUGR, Pregnancy
Interventions: Ultrasound, MRI, Blood collection, Neurological Function Assessment, Placental Analysis, Measurement of body fat, Pediatric heart ultrasound; Radiation · Procedure · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer
Interventions: Neoadjuvant Chemotherapy, Radiation Therapy, MRI, Breast Cancer Surgery, Biopsy, Biospecimen collection; Drug · Radiation · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Traumatic Brain Injury
Interventions: Telephone Outcome Assessment, In-Person Outcome Assessment, 3T Magnetic Resonance Imaging (MRI), Blood Draw; Behavioral · Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 11
States / cities: San Francisco, California • Charlestown, Massachusetts • Cincinnati, Ohio + 8 more

Conditions: Alzheimer Disease
Interventions: Not listed
Lead sponsor: Banner Health; Other
Eligibility: 50 Years to 80 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy
Interventions: Serum Total Protein Measurement with TS Meter-DSP and Refractix DSP; Device
Lead sponsor: Reichert, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Lauderhill, Florida

Conditions: Non Small Cell Lung Cancer
Interventions: Observational; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Tumor Imaging, Tumor Tissue Collection, Blood Sample Collection; Diagnostic Test · Procedure
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,065 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2032
U.S. locations: 18
States / cities: Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more

Search by objective public record fields.

Blood Donation Study for ALPCO Syphilis-T and Syphilis-NT Assay Development

Sex Hormone Therapy and Mucosal Tissues

Ghrelin Levels in Pancreatic Cancer Patients

A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation Toxicity

Bioenergetic Profiling and Cognition in GBM Patients

EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer

Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients

Reducing Self-Dehumanization to Examine Oxytocin and Suicide Risk

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

African American Alzheimer's Progression Markers - CSF and Neuro-Imaging

Study of CAR-T Therapy in Older Patients

Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock

Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing

Evaluation of Long-term Buprenorphine Plasma Exposure

Longitudinal Study of Intra-Uterine Growth Restriction

Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer

TRACK-TBI Longitudinal Biomarker Study

Evaluation of a Finger Prick Collection Method for Measuring Alzheimer's Disease Blood Biomarkers

Refractix DSP and TS Meter-DSP Measurement Comparison

Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)